Immune Effect of Newcastle Disease Virus DNA Vaccine with C3d as a Molecular Adjuvant = Immune Effect of Newcastle Disease Virus DNA Vaccine with C3d as a Molecular Adjuvant

다국어 초록 (Multilingual Abstract)

Newcastle disease is a serious infectious disease in the poultry industry. The commercial vaccines can only offer limited protection and some of them are expensive and need adjuvants. At present, DNA vaccines are widely used. However, the immune responses induced by DNA vaccines are too slow and low. Here, we constructed the transfer vectors with a different number of C3d as molecular adjuvants (n = 1, 2, 4, or 6), and the vectors were cloned into the optimal eukaryotic expression plasmid (pVAXI-optiF) that expressed the F gene of Newcastle disease virus (NDV), and named pVAXI-F(o)-C3d1, pVAXI -F(o)-C3d2, pVAXI-F(o)-C3d4, and pVAXI-F(o)-C3d6, respectively. Cell transfection test indicated that pVAXI-F(o)-C3d6 showed the highest expression. In vivo immunization showed that the chickens immunized with pVAXI-F(o)-C3d6 intramuscularly induced better immune responses than the chickens immunized with the other plasmids. The protective efficacy of pVAXI-F(o)-C3d6 was 80% after challenge with the highly virulent NDV strain F48E9. The results in this study showed that C3d6 could be used as a molecular adjuvant to quickly induce an effective immune response to control NDV.

참고문헌 (Reference)

1 Dortmans JC, "The viral replication complex is associated with the virulence of Newcastle disease virus" 84 : 10113-10120, 2010

2 Zhang Y, "The solvent at antigen-binding site regulated C3d-CR2 interactions through the C-terminal tail of C3d at different ion strengths:insights from molecular dynamics simulation" 1860 : 2220-2231, 2016

3 Dimitrov KM, "Temporal, geographic, and host distribution of avian paramyxovirus 1 (Newcastle disease virus)" 39 : 22-34, 2016

4 Zhao K, "Synthesis, characterization and immune efficacy of LDH@SiO2nanoparticles with shell-core structure as a delivery carrier for Newcastle disease virus DNA vaccine" 10 : 2895-2911, 2015

5 Wu Y, "Recombinant Newcastle disease virus (NDV/Anh-IL-2)expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy" 132 : 24-30, 2016

6 Nagai Y, "Proteolytic cleavage of the viral glycoproteins and its significance for the virulence of Newcastle disease virus" 72 : 494-508, 1976

7 Li GX, "Prime-boost immunization with HA/C3d DNA followed by a recombinant pseudorabies virus boost enhanced protective immunity against H3N2 swine influenza virus in mice" 88 : 345-351, 2010

8 Liu XF, "Pathotypical and genotypical characterization of Newcastle disease virus isolated from outbreaks in chicken and goose flocks in some regions of China during 1985-2001" 148 : 1387-1403, 2003

9 Oreskovic Z, "Oil-based adjuvants delivered intradermally induce high primary IgG2 immune response in swine" 114 : 41-43, 2017

10 Crépeaux G, "Nonlinear dose-response of aluminium hydroxide adjuvant particles: selective low dose neurotoxicity" 375 : 48-57, 2017

11 Wang G, "Non-thermal plasma for inactivated-vaccine preparation" 34 : 1126-1132, 2016

12 Kumar S, "Newcastle disease virus outbreaks in India:time to revisit the vaccine type and strategies" 33 : 3268-3269, 2015

13 Kim SH, "Newcastle disease virus as a vaccine vector for development of human and veterinary vaccines" 8 : 2-15, 2016

14 Li L, "Molecular mechanisms for enhanced DNA vaccine immunogenicity" 15 : 313-329, 2016

15 Morla S, "Molecular characterization of genotype XIIIb Newcastle disea se v irus f rom centra l India during 2006-2012: evidence of its panzootic potential" 99 : 83-86, 2016

16 Buonavoglia D, "Long-term immunogenicity and protection against Mycoplasma agalactiae induced by an oil adjuvant vaccine in sheep" 88 : 16-19, 2010

17 Tlaxca JL, "Live attenuated and inactivated viral vaccine formulation and nasal delivery:potential and challenges" 93 : 56-78, 2015

18 Xu GL, "Induction of protective and therapeutic antitumor immunity by a DNA vaccine with C3d as a molecular adjuvant" 28 : 7221-7227, 2010

19 Miller PJ, "Identification of new sub-genotypes of virulent Newcastle disease virus with potential panzootic features" 29 : 216-229, 2015

20 Wang J, "Genomic characterizations of a Newcastle disease virus isolated from ducks in live bird markets in China" 11 : e0158771-, 2016

21 Hao HF, "Genetic variation in V gene of class II Newcastle disease virus" 37 : 14-20, 2016

22 Suradhat S, "Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization" 83 : 79-92, 2001

23 Ramezanpour B, "Emergency deployment of genetically engineered veterinary vaccines in Europe" 34 : 3435-3440, 2016

24 Cardenas-Garcia S, "Effects of chicken interferon gamma on Newcastle disease virus vaccine immunogenicity" 11 : e0159153-, 2016

25 Cardenas-Garcia S, "Development of an improved vaccine evaluation protocol to compare the efficacy of Newcastle disease vaccines" 43 : 136-145, 2015

26 DiNapoli JM, "Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans" 27 : 1530-1539, 2009

27 Liu D, "Cloning of a gene fragment encoding chicken complement component C3d with expression and immunogenicity of Newcastle disease virus F gene-C3d fusion protein" 37 : 477-485, 2008

28 Musa HH, "Cloning and expression of FimA-C3d recombinant protein" 12 : 55-59, 2014

29 Steglich C, "Chimeric avian paramyxovirusbased vector immunization against highly pathogenic avian influenza followed by conventional Newcastle disease vaccination eliminates lack of protection from virulent ND virus" 3 : 65-72, 2014

30 Dempsey PW, "C3d of complement as a molecular adjuvant:bridging innate and acquired immunity" 271 : 348-350, 1996

31 Wang R, "Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites" 73 : 2863-2872, 2005

32 Baxter D., "Active and passive immunity, vaccine types, excipients and licensing" 57 : 552-556, 2007